Eli Lilly Launches Website for Community Oncologists

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 2
Volume 10
Issue 2

INDIANAPOLIS-Eli Lilly and Company has launched a new website for community medical oncologists and their staffs. The site, located at www.lillydirect.com, is designed to save oncology health care professionals time by streamlining many of their business-related responsibilities.

INDIANAPOLIS—Eli Lilly and Company has launched a new website for community medical oncologists and their staffs. The site, located at www.lillydirect.com, is designed to save oncology health care professionals time by streamlining many of their business-related responsibilities.

For example, using the new website, physicians can access several major wholesale distributors of oncology products at one time to place orders for chemotherapeutic agents.

Other features of the website include reimbursement assistance, patient messaging, medical information on Lilly oncology products, and links to information on Lilly and non-Lilly oncology clinical trials, publications, scientific meetings, and cooperative groups and associations.

Articles in this issue
Activated T Cells Can Alter Behavior of Leukemic B Cells
Response Continues for at Least 8 Months with Ibritumomab Tiuxetan
Chemotherapy Without Methotrexate Achieves Superb Results in Children With NHL
Iodine I 131 Tositumomab Induces Response in 70% of Patients Progressing After Rituximab
Synthetic Anthracycline Produces High Response Rates in SCLC
Ibritumomab Tiuxetan Produces 73% Response Rate in B-cell NHL
Rituximab Produces Clinical Responses in Even Steroid-Refractory Idiopathic Thrombocytopenic Purpura
G-CSF Might Prolong Rituximab Responses in NHL
Use of CAD Increases the Early Detection of Breast Cancer by 20%
Rituximab Plus Fludarabine May Be Good Alternative to Rituximab Plus CHOP
Student Cigarette Smoking Falls Significantly
Injectable COX-2 Inhibitor Effective in Postsurgery Pain
Patients’ Exercise Needs May Differ After Cancer Therapy
HAART Improves Survival in HIV-Positive NHL Patients
Liposomal Tretinoin Produces Impressive Responses in Refractory B-cell and T-cell Lymphomas
Recent Videos
Patients with cancer are subjected to fewer radiotherapy-induced toxicities because of newer, more advanced technologies.
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
An easy-to-access database allows one to see a patient’s cancer stage, prior treatment, and survival outcomes in a single place.
Related Content
Perioperative Enfortumab Vedotin Combo Has Potential as SOC in Cisplatin-Ineligible MIBC

Perioperative Enfortumab Vedotin Combo Has Potential as SOC in Cisplatin-Ineligible MIBC

Kristi Rosa
October 18th 2025
Article

Enfortumab vedotin plus pembrolizumab enhanced survival rates for patients with muscle-invasive bladder cancer not eligible for cisplatin chemotherapy.

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Exploring the ESMO 2025 Presentations That May Shift GU Oncology

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
October 16th 2025
Podcast

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Tiragolumab/Atezolizumab Does Not Meet PFS End Point in NSCLC

Tiragolumab/Atezolizumab Does Not Meet PFS End Point in NSCLC

Jason M. Broderick
October 18th 2025
Article

The SKYSCRAPER-03 trial revealed that tiragolumab plus atezolizumab failed to improve progression-free survival compared with durvalumab in NSCLC.

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Charting the Evolution of TKIs and Finding the Next Breakthrough in CML

Jorge E. Cortes, MD
October 13th 2025
Podcast

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

T-DXd significantly improved iDFS compared with T-DM1 across various patient subgroups in high-risk, HER2-positive primary breast cancer with residual invasive disease.

Adjuvant T-DXd Improves Efficacy vs T-DM1 in HER2-Positive Breast Cancer

Ashling Wahner
October 18th 2025
Article

T-DXd significantly improved iDFS compared with T-DM1 across various patient subgroups in high-risk, HER2-positive primary breast cancer with residual invasive disease.

Nine-year final results from the CheckMate 238 trial demonstrated that adjuvant nivolumab significantly improved time to second disease progression.

Adjuvant Nivolumab Improves Long-Term RFS vs Ipilimumab in Resected Melanoma

Kyle Doherty
October 18th 2025
Article

Nine-year final results from the CheckMate 238 trial demonstrated that adjuvant nivolumab significantly improved time to second disease progression.